Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 1, 1999, Pages 23-27

  Lehtimäki, Terho ^a,b   Lehtinen, Saara ^a,b   Solakivi, Tuna ^b   Nikkilä, Matti ^c   Jaakkola, Olli ^a   Jokela, Hannu ^b   Ylä Herttuala, Seppo ^d   Luoma, Jukka S ^d   Koivula, Timo ^b   Nikkari, Tapio ^a  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c Tampere City Hospital   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Autoantibodies; Coronary artery disease; Low density lipoproteins; Oxidized lipoproteins

Indexed keywords

AUTOANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

EID: 0032920559     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.1.23     Document Type: Article

References (33)

1. Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Ann Rev Med. 1992;43:219-225.
2. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32-40.
3. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989;86:1372-1376.
4. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
5. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: evidence that anti-oxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987;84:7725-7729.
6. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA. 1987;84:5928-5931.
7. Salonen JT, Ylä-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992; 339:883-887.
8. Ben-Yehuda O, Witztum JL, Keaney JF Jr, Frei B, Hankin B, Vita JA. Autoantibody titer to malondialdehyde modified low density lipoprotein correlates with extent of coronary artery disease. Circulation. 1996; 94:I638. Abstract.
9. Puurunen M, Mänttäri M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154:2605-2609.
10. Heitzer T, Ylä-Herttuala S, Luoma J, et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation. 1996;93: 1346-1353.
11. Raitakari OT, Pitkanen OP, Lehtimäki T, et al. Autoantibody against oxidized LDL and LDL particle size: relationships to coronary reactivity in young men. J Am Coll Cardiol. 1997;30:97-102.
12. Judgins MP. Selective coronary angiography. Radiology. 1967;89:492. Abstract.
13. Lippi U, Graziani MS, Manzato F, Schinella M. Assay of cholesterol in high-density lipoprotein in hypertriglyceridemic sera. Clin Chem. 1986; 32:2118. Abstract.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of plasma low density lipoprotein cholesterol concentration without use of preparative ultracentrifuge. Clin Chem. 1972;18:499. Abstract.
15. Uusitupa MI, Niskanen L, Luoma J, Vilja P, Mercuri M, Rauramaa R, Ylä-Herttuala S. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb. 1996;16:1236-1242.
16. Beaudeux JL, Guillausseau PJ, Peynet J, et al. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients. Clin Chim Acta. 1995;239:131-141.
17. van der Vijver LPL, Steyger R, van Poppel G, et al. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis. 1996;122:245-253.
18. Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet. 1992;339:1183-1186.
19. De Rijke YB, Verwey HF, Vogelezang CJ, et al. Enhanced susceptibility of low-density lipoproteins to oxidation in coronary bypass patients with progression of atherosclerosis. Clin Chim Acta. 1995;243:137-149.
20. Mironova M, Virella G, Lopes-Virella MF. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb. 1996; 16:222-229.
21. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20:707-727.
22. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
23. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Biol. 1995;369:39-48.
24. Evans PJ, Smith C, Mitchinson MJ, Halliwell B. Metal ion release from mechanically disrupted human arterial wall: implications for the development of atherosclerosis. Free Radic Res. 1995;23:465-469.
25. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990;1044:275-283.
26. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
27. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
28. Mackness MI, Arrol S, Durrington PN, Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286: 152-154.
29. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 1994;14:605-616.
30. Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Wittzum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. J Clin Invest. 1996;98:800-814.
31. Hörkkö I, Sohvi A, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Ware Branch D, Witzum JL. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest. 1996;98:815-825.
32. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Paluso T. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341: 923-925.
33. Vaarala O, Mänttäri M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palosuo T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23-27.